MYO at a glance
MYOMO, INC. (MYO, SEC CIK 1369290) filed its latest 10-K annual report on March 9, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on August 5, 2026 and Form 4 insider filings as recently as September 14, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), MYOMO, INC. (MYO) reported revenue of $40.9 million (up 25.7% from FY2024) and a net loss of $15.6 million. Diluted EPS was -$0.37.
- As of June 30, 2026, 15 institutional investment managers tracked by SignalX reported holding MYOMO, INC. (MYO) shares worth $3.7 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Kovelman Harry on September 11, 2026 of 15,488 shares at $1.27 per share.
- In the last 90 days, MYO insiders reported 0 open-market purchases ($0) and 4 open-market sales ($101K) on Form 4, a net sale of $101K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $40.9M
- +25.7% vs prior year
- Insiders · 90 days
- 0 buys · 4 sells
- Net −$101K
- 13F holders
- 15 funds
- $3.7M · −3 vs prior quarter
- Latest 8-K
- Aug 5, 2026
- Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business: Wearable myoelectric-controlled upper limb orthoses for neuromuscular disorders and paralysis
- New emphasis on upcoming MyoPro3 and MyoPal pediatric device to expand product lineup
- Strategic shift toward broader direct billing and increased sales through O&P providers and international markets, including EU and Canada
- Patient pipeline grows 10% to 1,528, backlog down 27% to 199 units, revenue up 26% in 2025 despite lower backlog
- CMS reimbursement updated Jan 1, 2026 at approx. $68,800 for powered grasp (L8702 code), providing clearer payer framework
Risk Factors
- CMS reclassification of MyoPro to brace benefit category effective January 1, 2024 enabling lump sum reimbursement around $34,970 to $68,800 per device
- Medicare Advantage plans reduced MyoPro authorizations causing 2% revenue decline in 2025; 20% of product revenues from these plans in 2025
- Reliance on Cogmedix as sole contract manufacturer for key subassemblies risks supply delays, regulatory compliance issues, and costly transfer of production
- Social media algorithm changes in Q1 2025 impaired lead generation, increasing advertising cost per addition to patient pipeline
- Loan and Security Agreement with Avenue in Nov 2025 secures $17.5 million funding with covenants requiring $2.5 million minimum cash and 75% of projected revenue
Management Discussion & Analysis
- Revenue $40.9M in 2025, up 26% YoY from $32.6M driven by higher volume and ASP; direct billing $30.4M (74% of total, +20%), International $6.8M (+48%), U.S. O&P $2.9M (doubled), VA $0.8M (-31%)
- Gross margin declined to 65.7% in 2025 from 71.2% in 2024, due to higher overhead capitalization changes and warranty expenses
- Best performing segment: International with 48% growth to $6.8M; worst performing segment: VA with 31% decline to $0.8M
- Cash used in operations $14.5M in 2025; capital expenditures approx. $3.3M including furniture, fixtures, and software; net proceeds $15.8M from Dec 2024 equity offering and $17.5M term loan facility raised in Nov 2025
- 2026 outlook: focus on recurring revenues from MyoConnect referrals and O&P providers, reducing direct advertising costs, managing fixed expenses and improving gross margin through volume and cost reductions; risk from dependence on insurance reimbursement
AI summary of the MYO 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Risk Factors
- Tariff exposure: 2026 import tariffs estimated to reduce gross margin by less than 100 basis points
- Trade-policy uncertainty: U.S.-Mexico-Canada Agreement renegotiation could modify or increase tariffs
- International expansion risk: limited experience with foreign regulatory environments may delay market penetration
- Growth execution risk: expanding Medicare Part B, O&P locations, and international distribution strains management and suppliers
- Currency risk: exchange-rate fluctuations could adversely affect international results of operations
AI summary of the MYO 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q2 FY2026 results for quarter ended June 30, 2026
- Full financial results furnished in Exhibit 99.1
Item EX-99.1: Item EX-99.1
- Q2 revenue $11.7M, up 21% YoY; full-year guidance raised to $45–47M, signaling stronger demand expectations
- Gross margin expanded to 72.1% from 62.7%, while operating expenses rose less than 1%, demonstrating operating leverage
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Amendment No. 1 corrects exhibit labels for the stock incentive plan and amended Certificate of Incorporation
- Filing adds required hyperlinks to improve access to governing documents
Item 5.07: Submission of Matters to a Vote of Security Holders
- Paul R. Gudonis and Thomas F. Kirk reelected as Class III directors through 2029
- Executive compensation approved with 13,715,583 votes favoring the advisory proposal
Item 5.07: Submission of Matters to a Vote of Security Holders
- Gudonis and Kirk reelected as Class III directors through 2029, with 15.1M and 14.3M affirmative votes
- Executive compensation approved in advisory vote, with 13.7M for and 696K against
AI summaries of MYO 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for MYO
Don't miss the next MYO filing
- Alerts as it files. A push when MYO files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut MYO, by share count.
- Ask anything. An AI agent that reads every MYO filing and answers with sources.
MYO alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Kovelman Harry | Sell | Sep 11, 2026 | 15,488 | $1.27 |
| Morris Milton Mayo | Sell | Sep 2, 2026 | 15,000 | $1.41 |
| Kovelman Harry | Sell | Aug 20, 2026 | 17,250 | $1.73 |
| Kovelman Harry | Sell | Aug 20, 2026 | 17,500 | $1.73 |
| GUDONIS PAUL R | A | Aug 7, 2026 | 146,909 | - |
| Mitchell Micah | F | Aug 7, 2026 | 21,559 | $1.42 |
| HENRY DAVID A | F | Aug 7, 2026 | 25,310 | $1.42 |
| Kovelman Harry | F | Aug 7, 2026 | 22,457 | $1.42 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $32.6M | $40.9M |
| Gross Profit | - | $23.2M | $26.9M |
| Operating Income | - | -$6.2M | -$14.4M |
| Net Income | - | -$6.2M | -$15.6M |
| Gross Margin | - | 71.2% | 65.7% |
| Op. Margin | - | -19.1% | -35.2% |
| Net Margin | - | -19.0% | -38.1% |
| Balance Sheet | |||
| Total Assets | $14.6M | $42.2M | $38.6M |
| Equity | - | $24.7M | $11.4M |
| ROE | - | -25.0% | -136.6% |
| Per Share | |||
| EPS | - | $-0.16 | $-0.37 |
| Cash Flow | |||
| Operating CF | - | -$3.3M | -$14.5M |
| CapEx | $146K | $1.4M | $1.7M |
Source: XBRL data in MYOMO, INC. (MYO)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate MYO share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 15 | $3.7M |
| Q1 2026 | 18 | $3.0M |
| Q4 2025 | 17 | $5.0M |
| Q3 2025 | 18 | $5.7M |
| Q2 2025 | 19 | $13.2M |
| Q1 2025 | 10 | $14.6M |
| Q4 2024 | 7 | $11.9M |
| Q3 2024 | 5 | $1.2M |
- AQR Capital Management+609.3K (+191%)
- Vanguard Capital Management LLC+492.2K (+43%)
- Renaissance Technologies LLC+24.9K (+106%)
- JPMorgan Chase & Co+13.9K (+94%)
- PNC Financial Services+994 (+24%)
- BlackRock−1.47M (-87%)
- State Street Corp−277.3K (-72%)
- Northern Trust−133.4K (-62%)
- Goldman Sachs Group−74.1K (-44%)
- Citigroup−16.8K (-94%)
- Millennium Management+271.3K
- Citadel Advisors LLC+102.5K
- Vanguard Portfolio Management LLC−205.6K
- BNY Mellon−70.5K
- Invesco Ltd−17.2K
- T. Rowe Price Group−16.6K
- Wells Fargo & Co−13.1K
Source: 13F-HR filings on SEC EDGAR (aggregated from 109 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
MYO filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Sep 14, 2026 | - | - | - |
| 4 | Sep 4, 2026 | - | - | - |
| 4 | Aug 24, 2026 | - | - | - |
| 4 | Aug 21, 2026 | - | - | - |
| 4 | Aug 11, 2026 | - | - | - |
| 4 | Aug 11, 2026 | - | - | - |
| 4 | Aug 11, 2026 | - | - | - |
| 4 | Aug 11, 2026 | - | - | - |
| 10-Q | Aug 5, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| 4 | Jul 13, 2026 | - | - | - |
| 4 | Jul 13, 2026 | - | - | - |
| 8-K | Jun 29, 2026 | - | Analysis | - |
| 4 | Jun 26, 2026 | - | - | - |
| 8-K | Jun 26, 2026 | - | Analysis | - |
| 4 | Jun 26, 2026 | - | - | - |
| 4 | Jun 26, 2026 | - | - | - |
| 4 | Jun 26, 2026 | - | - | - |
| 4 | Jun 26, 2026 | - | - | - |
| 4 | Jun 26, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 9, 2026 | - | - | |
| 4 | Jun 9, 2026 | - | - |
Related Health Care companies
- ALGN · Align TechnologyOrthopedic, Prosthetic & Surgical Appliances & Supplies
- AVR · Anteris Technologies Global Corp.Orthopedic, Prosthetic & Surgical Appliances & Supplies
- AVNS · AVANOS MEDICAL, INC.Orthopedic, Prosthetic & Surgical Appliances & Supplies
- EW · Edwards LifesciencesOrthopedic, Prosthetic & Surgical Appliances & Supplies
- ENOV · Enovis CORPOrthopedic, Prosthetic & Surgical Appliances & Supplies
- INGN · Inogen IncOrthopedic, Prosthetic & Surgical Appliances & Supplies
- ISRG · Intuitive SurgicalOrthopedic, Prosthetic & Surgical Appliances & Supplies
- LAKE · LAKELAND INDUSTRIES INCOrthopedic, Prosthetic & Surgical Appliances & Supplies
MYO SEC filings: frequently asked questions
Are MYO insiders buying or selling?
In the last 90 days, MYOMO, INC. (MYO) officers, directors and 10% owners reported no open-market purchases and 4 open-market sales worth $101,059 by 2 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold MYO stock?
As of June 30, 2026, the largest MYOMO, INC. (MYO) holders among the 13F filers tracked by SignalX were Vanguard Capital Management LLC ($1.7 million), AQR Capital Management ($966,000), Millennium Management ($282,000), BlackRock ($233,000), State Street Corp ($110,000). 13F-HR reports are filed up to 45 days after each quarter ends.
What was MYO's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), MYOMO, INC. (MYO) reported revenue of $40.9 million (up 25.7% from FY2024) and a net loss of $15.6 million. Diluted EPS was -$0.37. The figures come from the XBRL data in the 10-K.
What are the main risks in MYO's latest 10-K?
In the 10-K filed March 9, 2026, MYOMO, INC. (MYO) flagged: CMS reclassification of MyoPro to brace benefit category effective January 1, 2024 enabling lump sum reimbursement around $34,970 to $68,800 per device. Medicare Advantage plans reduced MyoPro authorizations causing 2% revenue decline in 2025; 20% of product revenues from these plans in 2025. (AI summary of the Risk Factors section.)
What did MYO report in its latest 8-K?
MYOMO, INC. (MYO) filed an 8-K on August 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q2 FY2026 results for quarter ended June 30, 2026.
What are the latest MYO SEC filings?
MYOMO, INC. (MYO) filed its latest 10-K annual report on March 9, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on August 5, 2026 and a Form 4 insider filing on September 14, 2026.
What is MYO's SEC CIK number?
MYOMO, INC. (MYO)'s SEC Central Index Key (CIK) is 1369290. EDGAR lists every MYO filing under that number.
Ask anything about MYO
The research agent reads MYO's filings, financials, insider trades and 13F holders, then answers with sources.